What's Happening?
The U.S. Department of Justice (DOJ) Civil Division and the U.S. Department of Health and Human Services (HHS) have jointly announced the Healthcare False Claims Act (FCA) Self-Disclosure Pilot Program (FCA SDPP). This new six-month initiative, launched
on October 22, 2026, aims to provide healthcare companies with a structured pathway to resolve civil liability under the federal FCA and certain HHS administrative authorities. The program encourages healthcare providers, suppliers, manufacturers, payors, and related entities to disclose potential FCA violations that were previously unknown to the federal government. Participating HHS components include the Office of the General Counsel, the Office of Inspector General (HHS-OIG), and the Centers for Medicare & Medicaid Services (CMS). The pilot program offers a coordinated civil release, a defined repayment multiplier range of 1.25 to 1.6 times the base self-disclosure repayment, and more favorable damage calculations in Anti-Kickback Statute (AKS) cases. Submissions must be made by April 22, 2027, and must include a detailed description of the conduct, supporting documents, remedial actions taken, and financial information for repayment calculation.
Why It's Important?
This pilot program is significant as it offers healthcare companies a degree of predictability and potentially more favorable terms for resolving FCA violations compared to existing self-disclosure protocols. By providing a defined multiplier range and avoiding the full value of claims in AKS-based FCA matters, the program aims to incentivize companies to proactively report misconduct. This could lead to quicker resolutions for the government, allowing it to reallocate resources towards more recalcitrant actors. For healthcare entities, the program offers the benefit of a coordinated civil release without factual admissions, and importantly, HHS-OIG will not require a corporate integrity agreement (CIA), nor will CMS impose civil monetary penalties (CMPs) or seek revocation. This could reduce the long-term operational and financial burdens associated with FCA resolutions, fostering a more transparent and compliant healthcare industry by encouraging self-policing.
What's Next?
Healthcare companies with potential FCA exposure now have a six-month window, until April 22, 2027, to submit self-disclosures under this pilot program. Companies are advised to quickly assess potential FCA issues, engage legal counsel, conduct internal investigations, and evaluate whether the benefits of this program outweigh the risks. They must also consider potential exposure under state FCA laws or other agencies, and how disclosed conduct might impact existing qui tam actions. The DOJ and HHS will monitor the program's implementation and outcomes, which could influence future enforcement strategies and the potential for similar programs. Companies should also prepare for the possibility that disclosed conduct, even if intended for civil resolution, could be referred for criminal investigation if deemed appropriate by the DOJ Civil Division.
Beyond the Headlines
The FCA SDPP introduces a strategic shift in how the government approaches healthcare fraud enforcement, moving towards encouraging voluntary compliance through defined incentives. However, the program also presents complexities and risks. Companies must navigate uncertainties such as unknowingly disclosing conduct already known to the government, the potential for criminal referrals despite civil intent, and the lack of guarantees for resolution once a disclosure is made. The requirement for a certification from an 'authorized representative' also raises questions about who should certify and the scope of due diligence needed, potentially creating individual and corporate exposure if the submission is later found to be inaccurate or incomplete. This initiative could set a precedent for future enforcement actions across various regulated industries, emphasizing self-reporting as a mechanism for more efficient resolution of legal liabilities.
